Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$264.32 USD

264.32
313,143

-7.86 (-2.89%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $264.62 +0.30 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Masimo (MASI) Launches UniView, Improves Patient Safety

by Zacks Equity Research

Masimo's (MASI) strategy to target hospitals and consumer market is likely to provide it a competitive edge in the U.S. MedTech sector.

    Zacks Equity Research

    Here's Why You Should Invest in ABIOMED (ABMD) Right Now

    by Zacks Equity Research

    ABIOMED's (ABMD) flagship Impella holds promise. A raised guidance encourages.

      Zacks Equity Research

      Cooper (COO) Buys LifeGlobal to Widen Fertility Device Line

      by Zacks Equity Research

      Cooper Companies' (COO) LifeGlobal asset purchase is likely to boost CooperSurgical.

        Zacks Equity Research

        Here's Why You Should Invest in Surmodics (SRDX) Right Now

        by Zacks Equity Research

        Surmodics (SRDX) continues to benefit from solid growth in the In Vitro Diagnostics (IVD) segment.

          Zacks Equity Research

          Boston Scientific to Acquire Securus Medical, Boost EP Unit

          by Zacks Equity Research

          Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.

            Zacks Equity Research

            IRCCO Picks Cerner's HealtheIntent for Patients of Illinois

            by Zacks Equity Research

            Cerner's (CERN) HealtheIntent intends to serve 20,000 Medicare patients in Illinois through IRCCO's accountable care organizations.

              Zacks Equity Research

              AngioDynamics (ANGO) Product Line Strong, Debt Level High

              by Zacks Equity Research

              AngioDynamics (ANGO) rides on promising NanoKnife performance. Dwindling sales are a concern.

                Zacks Equity Research

                Walgreens Boots' Retail Business Solid Amid Several Concerns

                by Zacks Equity Research

                Walgreens Boots (WBA) progresses with consistent sales rise in the Retail Pharmacy International business. Moreover, the stock grows on strategic alliances.

                  Zacks Equity Research

                  Here's Why You Should Invest in Masimo (MASI) Right Now

                  by Zacks Equity Research

                  Masimo (MASI) rides on solid earnings results and a wide array of products.

                    Zacks Equity Research

                    Accuray Radixact Picked by India's Apollo for Cancer Treatment

                    by Zacks Equity Research

                    Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.

                      Zacks Equity Research

                      Accuray's CyberKnife Treats First Patient at Erasmus MC

                      by Zacks Equity Research

                      Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.

                        Zacks Equity Research

                        Walgreens Boots (WBA) Beats on Earnings in Q2, Lifts View

                        by Zacks Equity Research

                        Walgreens Boots (WBA) witnesses revenue growth across all three segments in Q2. A solid guidance instills investor confidence in the stock.

                          Zacks Equity Research

                          Veeva Systems' Vault QMS to Manage Shionogi Product Quality

                          by Zacks Equity Research

                          Japan's Shionogi & Co. Ltd. adopts Veeva Systems' (VEEV) cloud-based Vault QMS to enhance product quality, both inside and outside Japan.

                            Zacks Equity Research

                            DENTSPLY to Acquire OraMetrix, Boost CAD-CAM Dental Unit

                            by Zacks Equity Research

                            The acquisition of OraMetrix is likely to bolster DENTSPLY's (XRAY) dental business.

                              Zacks Equity Research

                              Should You Buy Walgreens Boots (WBA) Ahead of Earnings?

                              by Zacks Equity Research

                              Walgreens Boots (WBA) witnesses improvement in sales at the Retail Pharmacy International segment.

                                Zacks Equity Research

                                Baxter (BAX) Banks on Portfolio Strength, Strategic Buyouts

                                by Zacks Equity Research

                                Baxter (BAX) gains on a slew of regulatory approvals and strategic collaborations.

                                  Zacks Equity Research

                                  Wright Medical Expands Product Index for Advanced Diagnosis

                                  by Zacks Equity Research

                                  Wright Medical (WMGI) introduces new products that are likely to augment its lower extremities and biologics business.

                                    Zacks Equity Research

                                    Here's Why You Should Steer Clear of DENTSPLY (XRAY) for Now

                                    by Zacks Equity Research

                                    DENTSPLY SIRONA (XRAY) faces foreign exchange woes and chances of margin decline in the quarters ahead.

                                      Zacks Equity Research

                                      Retail Pharmacy to Boost Walgreens Boots Amid Tough Contest

                                      by Zacks Equity Research

                                      Ahead of Walgreens Boots' (WBA) second-quarter fiscal 2018 results, we are upbeat about the stock's strength in Retail Pharmacy USA division and prescription growth on account of Medicare Part D.

                                        Zacks Equity Research

                                        Neogen (NEOG) Q3 Earnings Beat, Revenues Miss Estimates

                                        by Zacks Equity Research

                                        Neogen (NEOG) witnesses year-over-year revenue increase in both the segments in Q3.

                                          Zacks Equity Research

                                          Favorable Market Trend & Core Business Expansion Aid STERIS

                                          by Zacks Equity Research

                                          STERIS' (STE) string of six buyouts in fiscal 2018 keeps us upbeat about the stock. The same is expected to strengthen its Healthcare Specialty Services and Applied Sterilization Technologies arms.

                                            Zacks Equity Research

                                            LabCorp & Interpace Team Up, Drive Specialty Diagnostics

                                            by Zacks Equity Research

                                            Per the new deal with Interpace, Dianon Pathology, member of the LabCorp (LH) Specialty Testing Group, is supposed to perform the thyroid biopsy analysis.

                                              Zacks Equity Research

                                              DaVita (DVA) Banks on Kidney Care Unit Amid Labor Union Woes

                                              by Zacks Equity Research

                                              Davita's kidney care unit is gaining prominence worldwide. However, the company is grappling with labor-union woes in California and Ohio.

                                                Zacks Equity Research

                                                CVS Health's Pharmacy Services Remain Solid Amid Retail Drag

                                                by Zacks Equity Research

                                                CVS Health's (CVS) robust 2018 PBM selling season is an upside. We are also upbeat about the company's initiation of the crucial $69-billion acquisition of Aetna.

                                                  Zacks Equity Research

                                                  BioScrip's Dull 2017 Earnings a Woe, Core Business Robust

                                                  by Zacks Equity Research

                                                  BioScrip's (BIOS) strategy to specifically focus on core revenue mix hurts overall growth. However, the company's core infusion business remains strong.